Onkor · MiLA, AI prior authorization for oncology

How it works

From drug order to decision, without the fax queue.

MiLA follows every request through its whole life. Your team steps in only where judgment is needed.

Intake starts in the EHR

MiLA detects the drug order, pulls the clinicals, and auto-detects the regimen. No re-keying, no chart digging, no sticky notes.

Complete packets, routed right

Every submission is checked for completeness and sent through the right payer channel, so requests stop bouncing back for missing info.

Monitoring and appeals

MiLA watches every pending request, flags payer silence, and drafts appeals with clinical citations attached. Your team reviews and sends.

Inside MiLA

A look at the product.

Three of the screens your team would live in.

Screens from our working demo · sample data

Command Center

See what MiLA is doing, as it does it.

One screen shows live agent activity, revenue protection, and the day's priorities across every site. No more asking who touched what.

Live activity stream for every automated action
Pattern intelligence that spots payer behavior shifts
Priority queue ranked by risk and dollar value

Command Center

Live across all sites · updated every few seconds

LIVE

312Approved

47Pending review

9Needs escalation

$182KRecovered

MiLA agent activity

PA packet submitted · Keytruda J9271 · eviCoreClinicals auto-attached from EHR feed 2m

Appeal auto-drafted · UHC · ready for reviewNCCN pathway citation included 9m

72hr payer silence flagged · escalatedAssigned to queue owner with next step 14m

Regimen auto-detected from active drug orderSmart Intake opened the request 21m

Pattern intelligence

eviCorefriction

UHCfriction

Regencefriction

Pattern detectedeviCore requesting PET reports on immunotherapy since May. MiLA now attaches them up front.

Denial risk, before submission

Find out now, not in thirty days.

Every claim is ranked by denial risk before it goes out the door, so your team works the highest-stakes cases first and fixes gaps while they can still be fixed.

Denial likelihood scored per case, with the reasons shown
Revenue at risk quantified down to the claim
Recommended fixes before the payer ever sees it

High-Risk Queue

Flagged by MiLA · ranked by risk and dollar value

RANKED

CaseDenial riskRevenue at riskOwner

Keytruda · J9271 · immunotherapyMRN ••4482 · eviCore · service 07/14 HIGH · 78% $67,200 D. Reyes

Opdivo · J9299 · immunotherapyMRN ••1937 · UHC · service 07/16 ELEV · 61% $34,000 K. Wong

IMRT plan · 77301 · radiation oncMRN ••6620 · Aetna · service 07/18 ELEV · 54% $21,900 Auto

Chemo admin · 96413MRN ••8054 · Regence · service 07/19 LOW · 22% $8,400 Auto

Recommended before submission · Keytruda J9271Attach PET report · cite NCCN pathway in cover note · route via eviCore portal instead of fax

Drug Margin Intelligence

Your margin lives in the drugs. Watch it.

Buy-and-bill economics make oncology different. MiLA tracks margin erosion by drug, surfaces biosimilar switch opportunities, and flags underpayments down to the J-code.

Margin erosion tracked per drug, per payer
Biosimilar preferences you may not be capturing yet
Underpayments flagged against contracted rates, with appeals drafted

Drug Margin Intelligence

Margin erosion, biosimilars, and underpayment recovery

DAILY

Margin erosion by drug

Keytruda$79K

Opdivo$48.6K

Avastin$34K

Darzalex$18K

Herceptin$11K

Signals

Underpayment flagged · $8,420 · J9312Paid below contracted rate. Appeal drafted and ready for review.

Biosimilar switch opportunityTwo payers prefer Zirabev over Avastin. Capturing the preference avoids denials and protects margin.

Why oncology

Oncology prior auth is its own animal.

Six-figure drug regimens, NCCN pathway requirements, benefit carve-outs, and payers that change rules mid-course. Horizontal RCM tools treat it like any other specialty. MiLA is built for it. And oncology is first, not only: MiLA also serves orthopedic groups, spine practices, and surgery centers.

Buy-and-bill economics

Drug margin is the practice's margin. MiLA treats every authorization as a financial event, not a form, and tracks the dollars from order to payment.

Pathway-aware packets

Submissions carry the clinical story payers actually check: regimen, staging, and pathway citations assembled from the chart, not typed from memory.

The whole service line

Medical oncology is the start. MiLA also handles radiation and surgical oncology workflows, from IMRT and SBRT plans to procedure authorizations.

Security and trust

Boring by design, where it counts.

MiLA touches PHI and payer decisions, so the foundation is deliberately conservative.

01 HIPAA-eligible infrastructure

Built on HIPAA-eligible AWS services with encryption in transit and at rest.

02 Append-only audit log

Every action, human or automated, is recorded and cannot be quietly rewritten.

03 Role-based access

Roles determine what each user can see and do, per site and per service line.

04 PHI-safe by design

Minimum necessary data handling, with human review on every outbound appeal.

Prior authorization is a systems problem, not a people problem.

Command Center

High-Risk Queue

Drug Margin Intelligence

From drug order to decision, without the fax queue.

Intake starts in the EHR

Complete packets, routed right

Monitoring and appeals

A look at the product.

See what MiLA is doing, as it does it.

Command Center

MiLA agent activity

Pattern intelligence

Find out now, not in thirty days.

High-Risk Queue

Your margin lives in the drugs. Watch it.

Drug Margin Intelligence

Margin erosion by drug

Signals

Oncology prior auth is its own animal.

Buy-and-bill economics

Pathway-aware packets

The whole service line

Boring by design, where it counts.

If prior auth is eating your team's week, let's talk.